Piet Swart

542 total citations
17 papers, 421 citations indexed

About

Piet Swart is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Piet Swart has authored 17 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 6 papers in Pharmacology and 5 papers in Oncology. Recurrent topics in Piet Swart's work include Pharmacogenetics and Drug Metabolism (6 papers), RNA Interference and Gene Delivery (4 papers) and Metabolomics and Mass Spectrometry Studies (3 papers). Piet Swart is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), RNA Interference and Gene Delivery (4 papers) and Metabolomics and Mass Spectrometry Studies (3 papers). Piet Swart collaborates with scholars based in Switzerland, United States and Germany. Piet Swart's co-authors include Joel A. Krauser, François Natt, Jürg Hunziker, Markus Walles, Markus Zollinger, Eunju Hurh, Esther van de Kerkhof, Thomas Faller, Yi Jin and Gian Camenisch and has published in prestigious journals such as PLoS ONE, Drug Discovery Today and Drug Metabolism and Disposition.

In The Last Decade

Piet Swart

17 papers receiving 409 citations

Peers

Countries citing papers authored by Piet Swart

Since Specialization

Citations

This map shows the geographic impact of Piet Swart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Piet Swart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Piet Swart more than expected).

Fields of papers citing papers by Piet Swart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Piet Swart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Piet Swart. The network helps show where Piet Swart may publish in the future.

Co-authorship network of co-authors of Piet Swart

This figure shows the co-authorship network connecting the top 25 collaborators of Piet Swart. A scholar is included among the top collaborators of Piet Swart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Piet Swart. Piet Swart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Insights into Praziquantel Metabolism and Potential Enantiomeric Cytochrome P450–Mediated Drug-Drug Interaction 2020 ·Drug Metabolism and Disposition ·(unknown), (unknown), (unknown), Howard Burt, (unknown), (unknown), Nada Abla, Piet Swart, Dominique Perrin	6
2	A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the “Metabolites in Safety Testing” Regulatory Guidance 2018 ·Drug Metabolism and Disposition ·Simone Schadt, Bojan Bister, Swapan K. Chowdhury, Christoph Funk, Cornelis E. C. A. Hop, W. Griffith Humphreys, (unknown), (unknown), Mark Kagan, S. Cyrus Khojasteh, Angus N. R. Nedderman, Chandra Prakash, Frank Runge, (unknown), Douglas K. Spracklin, Piet Swart, Susanna Tse, (unknown), R. Scott Obach	78
3	The impact of early human data on clinical development: there is time to win 2016 ·Drug Discovery Today ·Piet Swart, (unknown), M. Simón, Esther van Duijn, Wouter H. J. Vaes	11
4	ADME studies of [5‐³H]‐2′‐O‐methyluridine nucleoside in mice: a building block in siRNA therapeutics 2016 ·Pharmacology Research & Perspectives ·(unknown), (unknown), Thomas Faller, Esther van de Kerkhof, Joel A. Krauser, (unknown), (unknown), (unknown), François Natt, Jürg Hunziker, Piet Swart	3
5	Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers 2015 ·Cancer Chemotherapy and Pharmacology ·(unknown), Lars Blumenstein, Ulrike Glaenzel, Yi Jin, (unknown), Annamária Jakab, (unknown), Katharine Hazell, Anuradha Mehta, Lucia Trandafir, Piet Swart	30
6	Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite 2014 ·Xenobiotica ·Joel A. Krauser, Yi Jin, Markus Walles, Ulrike Pfaar, James Sutton, Marion Wiesmann, Daniel Graf, (unknown), (unknown), Gian Camenisch, Piet Swart	29
7	Biodistribution and Metabolism Studies of Lipid Nanoparticle–Formulated Internally [3H]-Labeled siRNA in Mice 2014 ·Drug Metabolism and Disposition ·(unknown), (unknown), Thomas Faller, Esther van de Kerkhof, François Natt, Jürg Hunziker, (unknown), Iwan Beuvink, Keith Bowman, Jeremy L. Baryza, (unknown), Chandra Vargeese, Olivier Heudi, Markus Stoeckli, Joel A. Krauser, Piet Swart	43
8	Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation 2014 ·Drug Metabolism and Disposition ·Nenad Manevski, Piet Swart, Kamal K. Balavenkatraman, (unknown), Gian Camenisch, Olivier Kretz, Hilmar Schiller, Markus Walles, (unknown), Reto Wettstein, Dirk J. Schaefer, Peter Itin, Joanna Ashton‐Chess, François Pognan, Armin Wolf, (unknown)	37
9	Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers 2014 ·Cancer Chemotherapy and Pharmacology ·Markus Zollinger, (unknown), Eunju Hurh, (unknown), (unknown), Piet Swart	49
10	Aldehyde Oxidase Activity in Fresh Human Skin 2014 ·Drug Metabolism and Disposition ·Nenad Manevski, Kamal K. Balavenkatraman, (unknown), Piet Swart, Markus Walles, Gian Camenisch, Hilmar Schiller, Olivier Kretz, (unknown), Reto Wettstein, Dirk J. Schaefer, François Pognan, Armin Wolf, (unknown)	26
11	An iron stable isotope comparison between human erythrocytes and plasma 2014 ·Metallomics ·Friedhelm von Blanckenburg, Marcus Oelze, Dietmar G. Schmid, Kirsten van Zuilen, Hans-Peter Gschwind, (unknown), (unknown), Daniel Kaufmann, Piet Swart	23
12	Iron uptake and ferrokinetics in healthy male subjects of an iron-based oral phosphate binder (SBR759) labeled with the stable isotope⁵⁸Fe 2014 ·Metallomics ·Hans-Peter Gschwind, Dietmar G. Schmid, Friedhelm von Blanckenburg, Marcus Oelze, Kirsten van Zuilen, (unknown), (unknown), Daniel Kaufmann, Piet Swart	4
13	Metabolism and Disposition of the Metabotropic Glutamate Receptor 5 Antagonist (mGluR5) Mavoglurant (AFQ056) in Healthy Subjects 2013 ·Drug Metabolism and Disposition ·Markus Walles, (unknown), Yi Jin, M. RITZAU, Luc Alexis Leuthold, Joel A. Krauser, Hans-Peter Gschwind, David A. Carcache, Matthias Kittelmann, (unknown), Mike Ufer, Ralph Woessner, Abhijit Chakraborty, Piet Swart	23
14	Metabolism Studies of Unformulated Internally [3H]-Labeled Short Interfering RNAs in Mice 2013 ·Drug Metabolism and Disposition ·(unknown), (unknown), Thomas Faller, Esther van de Kerkhof, François Natt, Jürg Hunziker, Joel A. Krauser, Piet Swart	42
15	Metabolism of patupilone in patients with advanced solid tumor malignancies 2012 ·Investigational New Drugs ·Kevin R. Kelly, Markus Zollinger, (unknown), Eugene Tan, Alain C. Mita, Felix Waldmeier, Patrick Urban, (unknown), Yanfeng Wang, Piet Swart, Chris H. Takimoto, Monica Mita	2
16	A Unique Automation Platform for Measuring Low Level Radioactivity in Metabolite Identification Studies 2012 ·PLoS ONE ·Joel A. Krauser, Markus Walles, (unknown), Daniel Graf, Piet Swart	2
17	Tritium labeling of full‐length small interfering RNAs 2012 ·Journal of Labelled Compounds and Radiopharmaceuticals ·(unknown), François Natt, Jürg Hunziker, Joel A. Krauser, Hendrik Andres, Piet Swart	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact